Parataxis Korea, Inc. (KOSDAQ:288330)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,249.00
+157.00 (14.38%)
At close: Jan 27, 2026
-69.98%
Market Cap117.75B
Revenue (ttm)10.10M +834.3%
Net Income-17.01B
EPS-286.77
Shares Out106.08M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,618,740
Average Volume846,722
Open1,092.00
Previous Close1,092.00
Day's Range1,065.00 - 1,340.00
52-Week Range671.00 - 9,280.00
Beta1.98
RSI54.99
Earnings DateMar 20, 2026

About Parataxis Korea

Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomw... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 21
Stock Exchange KOSDAQ
Ticker Symbol 288330
Full Company Profile

Financial Performance

In 2024, Parataxis Korea's revenue was 2.18 million, a decrease of -97.82% compared to the previous year's 100.00 million. Losses were -19.76 billion, -53.32% less than in 2023.

Financial Statements